Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Company Overview - Regeneron is expected to report a year-over-year decline in earnings, with a projected EPS of $8.15, reflecting a decrease of 29.5% compared to the previous year [3] - Revenues are anticipated to be $3.34 billion, down 5.7% from the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised down by 6.49% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Regeneron is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +7.62% [12] Earnings Surprise Potential - Regeneron has a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [12] - Historically, Regeneron has beaten consensus EPS estimates three out of the last four quarters [14] Market Expectations - The stock price may increase if the actual earnings exceed expectations in the upcoming report, scheduled for August 1 [2] - Conversely, if the earnings miss expectations, the stock may decline [2] Industry Context - Alnylam Pharmaceuticals, another player in the biomedical sector, is expected to report a loss of $0.03 per share, indicating a significant year-over-year decline of 105.4% [18] - Alnylam's revenues are projected to be $671.11 million, up 1.7% from the previous year, with a substantial positive Earnings ESP of +831.25% [19][20]